Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. Earnings Recaps

AQST Health Care 2 recaps
Q3 2025 Nov 6, 2025

Aquestive Therapeutics demonstrated strong momentum heading into its Q3 2025 earnings, highlighted by increased awareness of its Anaphylm dibutepinephrine Sublingual Film program and preparations for a potential FDA approval.

Key takeaways
  • Nearly 25% of allergists have engaged with Aquestive's CME training, enhancing awareness of Anaphylm ahead of the FDA review due by January 31, 2026.
  • Strategic prelaunch activities for Anaphylm are on track, with marketing materials finalized and a supply chain ready for rapid production upon FDA approval.
  • Leadership restructuring aims to bolster efforts in both the Anaphylm launch and the Adrenaverse platform, including the appointment of Dr. Matthew Davis as Chief Development Officer.
  • The company anticipates initiating clinical trials for its AQST-108 program in January 2026, further expanding its product pipeline.
Full recap
Q2 2025 Aug 12, 2025

Aquestive Therapeutics reported steady progress toward the anticipated FDA approval of Anaphylm, an innovative sublingual film for treating severe allergic reactions, with substantial market potential amidst ongoing pre-commercial activities.

Key takeaways
  • Anaphylm is on track for a scheduled FDA action date of January 31, 2026, with no significant safety issues reported in the recent update.
  • The market for severe allergic reaction treatments is projected to expand from 5 million to 10 million prescriptions annually, potentially creating a $2 billion revenue opportunity.
  • Aquestive plans to launch a patient-first cash pay program to ensure immediate access to Anaphylm, addressing barriers to insurance coverage and enhancing patient accessibility.
  • The company has successfully completed its first in-house Advisory Committee meeting and is actively preparing for potential further discussions with key opinion leaders.
  • Ongoing international expansion efforts for Anaphylm are being pursued alongside pre-commercial activities, positioning the company strategically for market entry.
Full recap